References
- GrunzeHKasperSGoodwinGBowdenCMollerHJThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatmentWorld J Biol Psychiatry2004512013515346536
- HirschfeldRMAGuideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder2nd edArlington, VAAmerican Psychiatric Association2005
- BerkLHallamKTColomFEnhancing medication adherence in patients with bipolar disorderHum Psychopharmacol20102511620041478
- PerlisRHOstacherMJMiklowitzDJClinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD studyJ Clin Psychiatry20107129630320331931
- ScottJPopeMSelf-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalizationAm J Psychiatry20021591927192912411230
- PopeMScottJDo clinicians understand why individuals stop taking lithiumJ Affect Disord20037428729112738048
- SajatovicMDaviesMHroudaDREnhancement of treatment adherence among patients with bipolar disorderPsychiatr Serv20045526426915001726
- VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry200970Suppl 414619686636
- Gutierrez-RojasLJuradoDMartinez-OrtegaJMGurpeguiMPoor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sampleJ Affect Disord20101271–3778320576292
- ScottJTacchiMJA pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxisBipolar Disord2002438639212519098
- HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs20072191193617927296
- WilderCMElbogenEBMoserLLSwansonJWSwartzMSMedication preferences and adherence among individuals with severe mental illness and psychiatric advance directivesPsychiatr Serv20106138038520360277
- SajatovicMJenkinsJHIs antipsychotic medication stigmatizing for people with mental illnessInt Rev Psychiatry20071910711217464788
- JohnsonFROzdemirSManjunathRHauberABBurchSPThompsonTRFactors that affect adherence to bipolar disorder treatments: a stated-preference approachMed Care20074554555217515782
- McIntyreRSUnderstanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global surveyJ Clin Psychiatry200970Suppl 351119570496
- NewcomerJWHauptDWThe metabolic effects of antipsychotic medicationsCan J Psychiatry20065148049116933585
- Saphris® (Asenapine) [Package insert]Kenilworth, NJSchering-Plough (Merck and Co, Inc)2011
- McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJA 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesBipolar Disord20091167368619839993
- McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialJ Affect Disord2010122273820096936
- CalabreseJStetLKotariHAsenapine as adjunctive treatment for bipolar mania: results of a placebo-controlled 12-week study and 40-week extension [abstract]Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22–26; New Orleans, LARed Hook, NYCurran Associates
- McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension studyJ Affect Disord201012635836520537396
- McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine versus olanzapine in acute mania: a double-blind extension studyBipolar Disord20091181582619832806
- YoungRCBiggsJTZieglerVEMeyerDAA rating scale for mania: reliability, validity and sensitivityBr J Psychiatry1978133429435728692
- GuyWClinical global impressionsGuyWECDEU Assessment Manual for PsychopharmacologyWashington, DCUS Department of Health, Education and Welfare1976
- MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
- TamayoJMMazzottiGTohenMOutcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidolJ Clin Psychopharmacol20072712613417414234
- US Department of Health and Human ServicesAdult Treatment Panel III (ATP III) of the National Cholesterol Education Program.01-33052001 National Institutes of Health.
- BrooksJOIIIGoldbergJFKetterTASafety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program For Bipolar DisorderJ Clin Psychiatry20117224024720868629
- BaldwinDMayersASexual side effects of antidepressant and antipsychotic drugsAdv Psychiatr Treat20039202210
- [No authors listed.]Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorderMed Lett Drugs Ther201052920216523
- PerlisRHBakerRWZarateCAJrOlanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trialJ Clin Psychiatry2006671747175317196055
- VietaEBrugueEGoikoleaJMAcute and continuation risperidone monotherapy in maniaHum Psychopharmacol200419414514716711
- BogartGTChavezBSafety and efficacy of quetiapine in bipolar depressionAnn Pharmacother2009431848185619809011
- PotkinSGCohenMPanagidesJEfficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialJ Clin Psychiatry2007681492150017960962
- ShahidMWalkerGBZornSHWongEHAsenapine: a novel psychopharmacologic agent with a unique human receptor signatureJ Psychopharmacol200923657318308814
- GlassmanAHSchizophrenia, antipsychotic drugs, and cardiovascular diseaseJ Clin Psychiatry200566Suppl 651016107178
- DiefenbachGJWoolleySBGoetheJWThe association between self-reported anxiety symptoms and suicidalityJ Nerv Ment Dis2009197929719214043
- DilsaverSCAkiskalHSAkiskalKKBenazziFDose-response relationship between number of comorbid anxiety disorders in adolescent bipolar/unipolar disorders, and psychosis, suicidality, substance abuse and familialityJ Affect Disord20069624925816904187
- GhanbariREl MansariMShahidMBlierPElectrophysiological characterization of the effects of asenapine at 5-HT(1 A), 5-HT(2 A), alpha(2)-adrenergic and D(2) receptors in the rat brainEur Neuropsychopharmacol20091917718719116183